ArticleCureus2026
Twice-Daily Scrambler Therapy for a Patient With Spinocerebellar Ataxia Suffering From Refractory Neuropathic Back Pain: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinocerebellar ataxia (SCA) is a group of progressive neurodegenerative diseases. These patients often suffer from pain with multiple etiologies. Our patient suffers from distressing neuropathic back pain, which was only marginally alleviated with high-dose conventional antineuropathic agents while suffering from the side effects. A course of scrambler therapy was prescribed, and sustained relief of neuropathic back pain was achieved for at least eight weeks after completion of scrambler therapy. This is the first case of neuropathic pain in SCA to be treated with scrambler therapy, to the best of our knowledge. Compared with usual daily scrambler therapy sessions, our patient received twice-daily sessions. The main takeaways from our case are that 1) scrambler therapy is a potential treatment for neuropathic pain in SCA patients; 2) it can treat neuropathic pain refractory to conventional antineuropathic agents with the added benefit of reducing the requirement as well as side effects associated with conventional antineuropathic agents; and 3) twice-daily sessions are a potential alternative to standard daily sessions with positive logistical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.